Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Helminth therapy and multiple sclerosis.

Fleming JO.

Int J Parasitol. 2013 Mar;43(3-4):259-74. doi: 10.1016/j.ijpara.2012.10.025. Epub 2013 Jan 5. Review.

PMID:
23298637
2.

Helminth Therapy for MS.

Tanasescu R, Constantinescu CS.

Curr Top Behav Neurosci. 2015;26:195-220. doi: 10.1007/7854_2014_361. Review.

PMID:
25472634
3.

Helminths as governors of immune-mediated inflammation.

Elliott DE, Summers RW, Weinstock JV.

Int J Parasitol. 2007 Apr;37(5):457-64. Epub 2006 Dec 28. Review.

PMID:
17313951
4.

Helminth therapies: translating the unknown unknowns to known knowns.

Khan AR, Fallon PG.

Int J Parasitol. 2013 Mar;43(3-4):293-9. doi: 10.1016/j.ijpara.2012.12.002. Epub 2013 Jan 3. Review.

PMID:
23291459
5.

Helminth/Parasite treatment of multiple sclerosis.

Correale J.

Curr Treat Options Neurol. 2014 Jun;16(6):296. doi: 10.1007/s11940-014-0296-3.

PMID:
24744099
6.

Human helminth therapy to treat inflammatory disorders - where do we stand?

Helmby H.

BMC Immunol. 2015 Mar 26;16:12. doi: 10.1186/s12865-015-0074-3. Review.

7.

[Of worms and men--Administration of helminth products as an innovative approach to treatment of autoimmune diseases].

Sega Y, Versini M, Shoenfeld Y.

Harefuah. 2015 Jul;154(7):428-31, 470, 469. Review. Hebrew.

PMID:
26380461
8.

The hygiene theory harnessing helminths and their ova to treat autoimmunity.

Ben-Ami Shor D, Harel M, Eliakim R, Shoenfeld Y.

Clin Rev Allergy Immunol. 2013 Oct;45(2):211-6. doi: 10.1007/s12016-012-8352-9. Review.

PMID:
23325330
9.

Prerequisites for the pharmaceutical industry to develop and commercialise helminths and helminth-derived product therapy.

Tilp C, Kapur V, Loging W, Erb KJ.

Int J Parasitol. 2013 Mar;43(3-4):319-25. doi: 10.1016/j.ijpara.2012.12.003. Epub 2013 Jan 3. Review.

PMID:
23291462
10.

Translatability of helminth therapy in inflammatory bowel diseases.

Weinstock JV, Elliott DE.

Int J Parasitol. 2013 Mar;43(3-4):245-51. doi: 10.1016/j.ijpara.2012.10.016. Epub 2012 Nov 21. Review.

11.

Helminth mediated modulation of Type 1 diabetes (T1D).

Zaccone P, Cooke A.

Int J Parasitol. 2013 Mar;43(3-4):311-8. doi: 10.1016/j.ijpara.2012.12.004. Epub 2013 Jan 3. Review.

PMID:
23291464
12.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
13.

Helminth-host immunological interactions: prevention and control of immune-mediated diseases.

Elliott DE, Weinstock JV.

Ann N Y Acad Sci. 2012 Jan;1247:83-96. doi: 10.1111/j.1749-6632.2011.06292.x. Epub 2012 Jan 12. Review.

14.

Helminth infection and type 1 diabetes.

Zaccone P, Hall SW.

Rev Diabet Stud. 2012 Winter;9(4):272-86. doi: 10.1900/RDS.2012.9.272. Epub 2012 Dec 28. Review.

15.

The therapeutic helminth?

McKay DM.

Trends Parasitol. 2009 Mar;25(3):109-14. doi: 10.1016/j.pt.2008.11.008. Epub 2009 Jan 23.

PMID:
19167926
16.

Do We Need Worms to Promote Immune Health?

Weinstock JV.

Clin Rev Allergy Immunol. 2015 Oct;49(2):227-31. doi: 10.1007/s12016-014-8458-3. Review.

PMID:
25326880
17.

Helminths and multiple sclerosis: will old friends give us new treatments for MS?

Fleming JO.

J Neuroimmunol. 2011 Apr;233(1-2):3-5. doi: 10.1016/j.jneuroim.2011.01.003. Epub 2011 Feb 4. No abstract available.

PMID:
21295861
18.

Clinical trials of helminth therapy in autoimmune diseases: rationale and findings.

Fleming JO, Weinstock JV.

Parasite Immunol. 2015 Jun;37(6):277-92. doi: 10.1111/pim.12175. Review.

19.

Worm therapy: for or against?

Pritchard D.

J Helminthol. 2011 Sep;85(3):225-7. doi: 10.1017/S0022149X11000204. Epub 2011 Jun 2.

PMID:
21729383
20.

Supplemental Content

Support Center